VertaPlex® HV radiopaque bone cement
VertaPlex® HV radiopaque bone cement is a high viscosity cement that contributes to a controlled interdigitation and fill. VertaPlex® HV radiopaque bone cement reaches a thick viscosity when it’s mixed and maintains viscosity for an average of 18 minutes1 giving physicians more working time.
In 2008, VertaPlex® HV radiopaque bone cement was released, addressing specific viscosity and working time preferences for treating vertebral compression fractures.
VertaPlex® HV radiopaque bone cement is indicated for the fixation of pathological fractures of the vertebral body using vertebroplasty or kyphoplasty. It is also indicated for the fixation of pathological fractures of the sacral vertebral body or ala using sacral vertebroplasty or sacroplasty. Painful vertebral compression fractures may result from osteoporosis, benign lesions (hemangioma), and malignant lesions (metastatic cancers, myeloma).
When used in conjunction with ES2® Augmentable Spinal System, VertaPlex® High Viscosity (HV) radiopaque bone cement is intended to restore the integrity of the spinal column even in the absence of fusion for a limited time period in patients with advanced stage tumors involving the thoracic and lumbar spine in whom life expectancy is of insufficient duration to permit achievement of fusion. VertaPlex® High Viscosity (HV) radiopaque bone cement and the ES2® Augmentable Spinal System are for use together at spinal levels where the structural integrity of the spine is not severely compromised.
Features2
- Immediate high viscosity after mixing
- Controlled interdigitation and fill
- Working time – approximately 18 minutes1
- Set time of 10.2 minutes at 37ºC
- Increased viscosity improves visibility
- 30% barium sulfate concentration
References
- Independent lab results from Fluid Dynamics Inc. commissioned by Stryker July 2009. Testing conducted at 20-21° C (68-70° F).
- Bone Cements Clinical Evaluation Report (12 December 2019)
Disclaimer
Bone cement: serious adverse events, some with fatal outcome, associated with the use of bone cements for vertebroplasty, kyphoplasty and sacroplasty include myocardial infarction, cardiac arrest, cerebrovascular accident, pulmonary embolism and cardiac embolism. Although it is rare, some adverse events have been known to occur beyond a year or more postoperatively. Additional risks exist with the use of bone cement. Please see the IFU for a complete list of potential risks. A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient.
Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery. The information presented is intended to demonstrate the breadth of Stryker product offerings.
A surgeon must always refer to the package insert, product label and/or instructions for use before using any Stryker product. The products depicted are CE marked in accordance with applicable EU Regulations and Directives. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area.
2020-27613